Superficial Bladder Cancer Metastatic to the Lungs: Two Case Reports and Review of the Literature

Urology ◽  
2009 ◽  
Vol 73 (1) ◽  
pp. 210.e3-210.e5 ◽  
Author(s):  
David W. Dougherty ◽  
Victoria K. Gonsorcik ◽  
Lewis E. Harpster ◽  
J.C. Trussell ◽  
Joseph J. Drabick
2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Nathaniel D. Coddington ◽  
Jesse K. Sandberg ◽  
Chen Yang ◽  
Jennifer K. Sehn ◽  
Eric H. Kim ◽  
...  

Background. Intravesicular Bacillus Calmette-Guérin (BCG) is an effective adjunctive therapy for superficial bladder cancer that has been shown to delay recurrence and progression of disease. Serious side effects are relatively rare but are difficult to diagnosis and commonly overlooked. Case Presentation. We report the case of a patient who was found to have mycotic aortic aneurysms secondary to treatment with BCG after a prolonged course with multiple intervening hospitalizations. Conclusion. Through this report, we discuss our present understanding of BCG infection following treatment and review the literature regarding this particular rare manifestation.


2006 ◽  
Vol 6 ◽  
pp. 2617-2625 ◽  
Author(s):  
Richard J. Sylvester

Superficial bladder cancer encompasses patients with stage Ta T1 tumors and patients with carcinomain situ(CIS). The natural history or treatment-related prognosis of these patients varies considerably from one patient to the next based on the patient’s clinical and the tumor's pathological characteristics. Based on a review of the literature, the most important prognostic factors for recurrence are the prior recurrence rate, number of tumors, and tumor size; whereas for progression, the most important prognostic factors are the T category, grade, and presence of CIS. Treatment with intravesical bacillus Calmette-Guerin reduces both the risk of recurrence and the risk of progression, and is the treatment of choice in high-risk papillary tumors and in patients with CIS. Assessment of a patient's prognostic factors and his or her risk of recurrence and progression is a prerequisite for determining the most appropriate treatment and frequency of follow-up for a given patient.


2013 ◽  
Vol 6 (3) ◽  
pp. 155-162 ◽  
Author(s):  
Katelin Mirkin ◽  
Jessica T. Casey ◽  
Shubhra Mukherjee ◽  
Stephanie J. Kielb

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Nigel P. Murray ◽  
Cynthia Fuentealba ◽  
Isidora Salazar ◽  
Aníbal Salazar ◽  
Marco Antonio Lopez ◽  
...  

Myelodysplasia is a clonal disorder characterized by progressive cytopenias. Intravescial BCG is standard immunotherapy for superficial bladder cancer. We present a patient with transfusion-dependent myelodysplasia whose blood counts normalized during treatment with intravesical BCG for bladder cancer. After finishing treatment, the patient became transfusion dependent once more. We discuss possible mechanisms to explain this case report.


2007 ◽  
Vol 177 (4S) ◽  
pp. 519-519
Author(s):  
Ofer Nativ ◽  
Renzo Colombo ◽  
Dov Engelstein ◽  
Ofer N. Gofrit ◽  
Thomas Akkad ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 205-205
Author(s):  
Henrik Suttmann ◽  
Josef Riemensberger ◽  
Andreas Böhle ◽  
Dieter Jocham ◽  
Sven Brandau

2006 ◽  
Vol 175 (4S) ◽  
pp. 268-269 ◽  
Author(s):  
Jessie L. Au ◽  
Robert A. Badalament ◽  
M. Guillaume Wientjes ◽  
Donn C. Young ◽  
Tong Shen ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 99-99
Author(s):  
Vincenzo Serretta ◽  
Vincenzo Altieri ◽  
Giuseppe Morgia ◽  
Rosalinda Allegro ◽  
Alessandra Di Lallo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document